拓扑异构酶Ⅰ抑制剂与肿瘤耐药的相关性研究进展
摘要
TOPO Ⅰ是调节核酸拓扑构型的关键酶,已成为重要的抗癌药物研究新靶点。肿瘤对细胞TOPOⅠ抑制剂产生耐药是一个相当复杂的细胞生理化过程,也是化疗失败的重要原因。喜树碱类药物是经典的TOPO Ⅰ抑制剂,一些非喜树碱类TOPO Ⅰ抑制剂也见报道。
出处
《国际肿瘤学杂志》
CAS
2004年第S1期82-85,共4页
Journal of International Oncology
参考文献12
-
1Azzariti A,Xu JM,Porcelli L,et al.7-Ethyl-10-Hydroxy-cam-ptothercin (SN-38) in combination with Gefitinib (Iressa? ZD1839). Biochemical Pharmacology . 2004 被引量：1
-
2Beidler DR,Chang JY.Zhou BS,et al.Camptothecin resistance Involving steps subsequent to the formation of protein -linked ONAbreaks in human camptothecin-resistant kB cell line. Cancer Research . 1996 被引量：1
-
3Cummings J,Zelcer N,Allen JD,et al.Glucuronidation as a mechnism of intrinsic drug resistance in colon cancer cells : contribution of drug transport proteins. Biochemical Pharmacology . 2004 被引量：1
-
4Sliutz GiKrlseder J,Tempfer C,et al.Drug resistance against gemcitaine and topotecan mediated by constitutive hsp70 overexpression in vitro.implication of quercetin as sensitiser in chemotherapy. British Journal of Cancer . 1996 被引量：1
-
5Allen JD,Brindhuis RF,Vandeemter L,et al.Extensive contribution of the multidrug transporters p-glycoprotein and Mrp1 to basal drug resistance. Cancer Research . 2000 被引量：1
-
6Koike K,Kawabe T,Tanaka T,et al.A canalicular multispeific organic anion transporter antisense enhances drug sensitivity in human hepatic cancer cells. Cancer Research . 1997 被引量：1
-
7Silva KL,Vasoncelos FC,Mauques-Santos LF,et al.CPT-11-induced cell death in leukemic cells is not affected by the MDR phenotype. Leukemia Research . 2003 被引量：1
-
8Jansen WJ,Hulscher TM,van Ark-Otte J,et al.CPT-11 sesitivity in relation to the expresion of P170-glycoprotein and multidrug resistane-associated protein. British Journal of Cancer . 1998 被引量：1
-
9Ting CY,Hsu CT,Hsu HT,et al.Isodiospyrin as novel human DNA topoisomerase 1 inhibitor. Biochemical Pharmacology . 2003 被引量：1
-
10Komatani H,Kotani H,Hara Y,et al.Identification of breast cancer res-istant protein/mitoxantrone resistandce/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, Topoisomerase I Inhibitors with an Indolocarbazole structure. Cancer Research . 2001 被引量：1
-
1陈丽花.拓扑替康联合奈达铂治疗晚期卵巢癌临床观察[J].山东医药,2008,48(27):23-23. 被引量：1
-
2罗云,娄世锋,陈林,陈姝,周慷.拓扑替康联合阿糖胞苷二线治疗血液恶性肿瘤的临床观察[J].医学临床研究,2004,21(2):183-184.
-
3ChaoHH.肺癌化疗的新进展：拓扑替康和拓扑异构酶I抑制剂的作用[J].结核病与胸部肿瘤,2002(4):288-288.
-
4张晨瑶,孙巍,苏加强,李维娟,谢晓霞.醛氢叶酸氟尿嘧啶与羟基喜树碱联合化疗治疗胃癌的近期疗效[J].黑龙江医学,1999(9):25-25.
-
5张文珏,周宗玫,王绿化,吕纪马,陈东福,梁军,张红星.放疗同步拓扑替康治疗局部晚期非小细胞肺癌的Ⅱ期临床研究[J].中华放射医学与防护杂志,2013,33(4):405-407. 被引量：7
-
6张力,宁晓红,毕洪霞,李龙芸.拓扑替康在小细胞肺癌中的应用[J].中国新药杂志,2001,10(10):743-746. 被引量：4
-
7王锋,秦叔逵,施毅.喜树碱类药物治疗晚期非小细胞肺癌的临床研究进展[J].临床肿瘤学杂志,2008,13(11):1047-1052. 被引量：1
-
8孟繁浩,巩丽颖,佟馨.抗癌药物——喜树碱类衍生物研究进展[J].生命的化学,2002,22(3):265-267. 被引量：17
-
9周燕华,胥彬.喜树碱类药物在癌症联合化疗应用中的新进展[J].肿瘤,1998,18(4):302-303. 被引量：23
-
10梁永钜,符立梧,等.拓扑异构酶Ⅰ和Ⅱ抑制剂联合治疗鼻咽癌的实验研究[J].中国药理通讯,2002,19(4):47-47.
